Management of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study

American Journal of Ophthalmology

Volumn 141, Issue 6, 2006, Pages

  Kymes, Steven M ^a   Kass, Michael A ^a   Anderson, Douglas R ^b   Miller, J Philip ^a   Gordon, Mae O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE; COHORT ANALYSIS; CONSENSUS; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; HYPOTHESIS; INCIDENCE; INTRAOCULAR HYPERTENSION; MEDICAL DECISION MAKING; OPEN ANGLE GLAUCOMA; PATIENT CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYMPTOM;

EID: 33744811979     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.01.019     Document Type: Article

References (53)

1. Lighthouse International. New approach to assessing glaucoma risk may help physicians decide who needs treatment: vision connections, 2005. Last accessed: December 15, 2005. Available at: http://www.visionconnection.org/Content/ForProfessionals/PatientManagement/DiseaseManagement/Glaucoma/default.htm
2. Friedman D.S., Congdon N., Kempen J., and Tielsch J.M. Vision problems in the United States (2002), National Eye Institute, Washington, DC. http://www.nei.nih.gov/eyedata/pdf/VPUS.pdf Last accessed: December 15, 2005. Available at: http://www.nei.nih.gov/eyedata/pdf/VPUS.pdf
3. Sommer A., Tielsch J.M., Katz J., et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 325 (1991) 1412-1417
4. Leske M.C. The epidemiology of open-angle glaucoma. Am J Epidemiol 118 (1983) 166-191
5. Gordon M.O., Beiser J.A., Brandt J.D., et al. The Ocular Hypertension Treatment Study. baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 714-720
6. Varma R., Ying-Lai M., Francis B.A., et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos. The Los Angeles Latino Eye Study. Ophthalmology 111 (2004) 1439-1448
7. Eddy D.M. Practice policies and guidelines. Where do they come from?. In: Burns J.E. (Ed). Clinical decision making. from theory to practice (1996), Jones and Bartlett, Sudbury (MA) 26-33
8. Kass M.A., Heuer D.K., Higgenbotham E.J., et al. The Ocular Hypertension Treatment Study. a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
9. Robin A.L., Frick K.D., Katz J., Budenz D., and Tielsch J.M. The Ocular Hypertension Treatment Study. Intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease?. Arch Ophthalmol 122 (2004) 376-378
10. Jampel H.D. Glaucoma patients' assessment of their visual function and quality of life. Trans Am Ophthalmol Soc 99 (2001) 301-317
11. Parrish R.K., Gedde S.J., Scott I.U., et al. Visual function and quality of life among persons with glaucoma. Arch Ophthalmol 115 (1997) 1447-1455
12. Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. Methods for the economic evaluation of health care programmes. 2nd ed. (1997), Oxford University Press, Oxford, UK 305
13. Gordon M.O., and Kass M.A. The Ocular Hypertension Treatment Study. design and baseline description of the participants. Arch Ophthalmol 117 (1999) 573-583
14. Lee P.P., Walt J., Doyle J.J., et al. A multi-center, retrospective pilot study of resource utilization and costs associated with severity of disease in glaucoma. Arch Ophthalmol 124 (2006) 12-19
15. Hodapp E., Parrish R.K., and Anderson D.R. Clinical decisions in glaucoma (1993), Mosby, St Louis
16. Beck J.R., and Pauker S.G. The Markov process in medical prognosis. Med Decis Making 3 (1983) 419-458
17. Dielemans I., Vingerling J.R., Wolfs R.C.W., Hofman A., Grobbee D.E., and de Jong P.T.V.M. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 101 (1994) 1851-1855
18. In: Medical Economics Staff, editors. 2005 Drug topics red book. Montvale (NJ): Thomson Medical Economics; 2005.
19. Meads C., and Hyde C. What is the cost of blindness?. Br J Ophthalmol 87 (2003) 1201-1204
20. Clancy C.M., and Eisenberg J.M. Outcomes research. measuring the end results of care. Science 282 (1998) 245-246
21. Tsevat J. What do utilities measure?. Med Care 38 (2000) S160-S164
22. Brown G.C., Sharma S., Brown M.M., and Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 118 (2000) 47-51
23. Jampel H.D., Schwartz A., Pollack I., Abrams D., Weiss H., and Miller R. Glaucoma patients' assessment of their visual function and quality of life. J Glaucoma 11 (2002) 154-163
24. Rabin R., and de Charro F. EQ-5D. a measure of health status from the EuroQol Group. Ann Med 33 (2001) 337-343
25. Kymes S.M., and Frick K.D. Value based medicine. let's get it right. [letter]. Br J Ophthalmol 89 (2005) 643-644
26. Brown M.M., Brown G.C., Sharma S., Kistler J., and Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol 85 (2001) 327-331
27. Ubel P.A., Hirth R.A., Chernew M.E., and Fendrick A.M. What Is the Price of Life and Why Doesn't It Increase with the Rate of Inflation?. Arch Intern Med 163 (2003) 1637-1641
28. Gillick M.R. Medicare coverage for technological innovations. Time for new criteria?. N Engl J Med 350 (2004) 2199-2203
29. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York 425
30. Busbee B.G., Brown M.M., Brown G.C., and Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology 110 (2003) 2310-2317
31. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices: modeling studies. Value Health 6 (2003) 9-17
32. Doubilet P., Begg C.B., Weinstein M.C., Braun P., and McNeil B.J. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 5 (1985) 157-177
33. Leske M.C., Wu S.-Y., Nemesure B., and Hennis A. Risk factors for incident nuclear opacities. Ophthalmology 109 (2002) 1303-1308
34. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., and Hussein M. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol 120 (2002) 1268-1279
35. Stinnett A.A., and Mullahy J. Net health benefits. a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18 (1998) S68-S80
36. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty. the role of cost-effectiveness acceptability curves. Health Econ 10 (2001) 779-787
37. Weene L.E. Ocular hypertension treatment study results could be misconstrued. [letter, comment]. Arch Ophthalmol 121 (2003) 1070
38. Mansberger S.L. A risk calculator to determine the probability of glaucoma. J Glaucoma 13 (2004) 345-347
39. Medeiros F.A., Weinrab R.N., Sample P.A., et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol 123 (2005) 1351-1360
40. Friedman D.S., Wilson M.R., Liebmann J.M., Fechtner R.D., and Weinrab R.N. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 138 (2004) S19-S31
41. Higginbotham E.J., Gordon M.O., Beiser J.A., et al. The Ocular Hypertension Treatment Study. topical medication delays or prevents primary open-angle glaucoma in African-American individuals. Arch Ophthalmol 122 (2004) 813-820
42. Leske M.C., Connell A.M.S., Wu S.-Y., et al. Incidence of open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol 119 (2001) 89-95
43. Mukesh B.N., McCarty C.A., Rait J.L., and Taylor H.R. Five-year incidence of open-angle glaucoma. Ophthalmology 109 (2002) 1047-1051
44. Revicki D.A., and Frank L. Pharmacoeconomic evaluation in the real world. effectiveness versus efficacy studies. Pharmacoeconomics 15 (1999) 423-434
45. Weiss N.S. Clinical epidemiology. the study of the outcome of illness. 2nd ed. (1996), Oxford University Press, New York
46. Jampel H.D., Schwartz G.F., Robin A.L., Abrams D.A., Johnson E., and Miller R.B. Patient preferences for eye drop characteristics. Arch Ophthalmol 121 (2003) 540-546
47. Lee D.J., Gomez-Marin O., Lam B.L., and Zheng D.D. Glaucoma and survival. Ophthalmology 110 (2003) 1476-1483
48. Age-related Eye Disease Study Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study. Arch Ophthalmol 122 (2004) 716-726
49. Leske M.C. Glaucoma and mortality. a connection. [guest editorial]. Ophthalmology 110 (2003) 1473-1475
50. McCarty C.A., Nanjan M., and Taylor H.R. Vision impairment predicts five year mortality. Br J Ophthalmol 85 (2001) 322-326
51. Hattenhauer M.G., Johnson D.H., Ing H.H., et al. The probability of blindness from open-angle glaucoma. Ophthalmology 105 (1998) 2099-2104
52. Anderson R.N. Method for constructing complete annual US life tables. vital and health statistics (1999), National Center for Health Statistics, Hyattsville (MD)
53. Lairson D.R., Begley C.G., Reynolds T.F., and Wilhemus K.R. Prevention of herpes simplex virus eye disease. Arch Ophthalmol 121 (2003) 108-112